



Universiteit
Leiden

The Netherlands

Exploring the role of homologous recombination deficiency and BRCA1/2 mutations in endometrial cancer

Jonge, M.M. de

Citation

Jonge, M. M. de. (2021, September 28). *Exploring the role of homologous recombination deficiency and BRCA1/2 mutations in endometrial cancer*. Retrieved from <https://hdl.handle.net/1887/3214105>

Version:

Publisher's Version

License:

[Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from:

<https://hdl.handle.net/1887/3214105>

Note: To cite this publication please use the final published version (if applicable).

Exploring the role of homologous recombination deficiency and *BRCA1/2* mutations in endometrial cancer

1. Endometrial cancer is part of the *gBRCA1/2*-associated hereditary breast and ovarian cancer (HBOC) syndrome. – *This thesis*
2. A typical *gBRCA1/2*-associated endometrial carcinoma is *TP53* mutated and is of high-grade. – *This thesis*
3. Homologous recombination deficiency frequently occurs in *TP53* mutated endometrial carcinomas, giving rise to new treatment opportunities. – *This thesis*
4. Tumor-first genetic testing for hereditary cancer syndromes is more efficient and should become standard clinical practice. – *This thesis*
5. Now that molecular characterization of cancers is becoming more and more relevant for diagnostic subclassification of tumors and for precision medicine, pathologist should be trained as morpho-molecular pathologist. – *Inspired by Moore et al. J Clin Pathol. 2018;71(4):285-290.*
6. When implementing tumor-first genetic testing as a routine part of pre-screening for hereditary variants, a multidisciplinary approach with a good collaboration between the pathology department and the clinical genetics department is essential to prevent interpretive errors of detected variants.
7. The opinion of the *BRCA1/2* mutation carrier should be considered when making a decision on the extent of risk-reducing surgery, and whether or not to extent the risk-reducing salpingo-oophorectomy with a hysterectomy (“shared decision-making”).
8. An increased risk is not the same as a high risk. Researches should be encouraged also to present absolute measures (e.g. absolute risks).
9. “Absence of evidence does not equal evidence of absence.” – Adapted from *Carl Sagan, 1997.*
10. People should more often be uncomfortably uncertain than comfortably wrong. – Adapted from *Ozan Varol “think like a rocket scientist”, 2020.*
11. In alle dagen zit goud verstopt. – Adapted from *Maris A.M, “geef me je echt”, 2021*